While both CTLA-4 and PD-1 mAbs have resulted in increased patient survival in numerous cancer types such as melanoma or non-small cell lung cancer (NSCLC), ICI still include important limitations. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.